Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 4747-year-old woman with diffuse large B-cell lymphoma is currently undergoing cyclical CHOP chemotherapy. Seven days after her last cycle, she presents to the emergency department with severe chills and a temperature of 39.4∘C39.4^{\circ}\text{C} (102.9∘F102.9^{\circ}\text{F}). Her absolute neutrophil count (ANC) is determined to be 110 cells/mm3110 \text{ cells/mm}^3. She has a peripherally inserted central catheter (PICC) in place. Arrange the following diagnostic, monitoring, and therapeutic steps in the most appropriate chronological sequence for the management of this patient's neutropenic fever.

  1. 1Obtain two sets of blood cultures, including one from the peripherally inserted central catheter, prior to any pharmacologic intervention.
  2. 2Administer an empiric intravenous antipseudomonal beta-lactam agent within 6060 minutes of triage.
  3. 3Evaluate the daily absolute neutrophil count and fever curve to assess the clinical response to initial empiric therapy.
  4. 4Initiate empiric systemic antifungal therapy if the patient remains persistently febrile and neutropenic after 44 to 77 days of antibacterial treatment.
  5. 5Discontinue the empiric antimicrobial regimen once the patient demonstrates sustained defervescence and the absolute neutrophil count recovers to strictly greater than 500 cells/mm3500 \text{ cells/mm}^3.

Answer

The correct sequence mandates drawing blood cultures first, immediately followed by the administration of empiric antipseudomonal antibiotics. Ongoing monitoring of the absolute neutrophil count and fever curve dictates the next steps: adding empiric antifungals if fever persists for 4 to 7 days, and ultimately discontinuing all antimicrobials once the neutrophil count recovers above 500 cells/mm³.
The precise chronological protocol for managing high-risk febrile neutropenia begins with immediate diagnostic blood cultures (Item 1) to secure pathogen identification before the bloodstream is altered by treatment. Because of the high mortality risk, empiric antipseudomonal antibiotics must be administered within a strict 60-minute window following cultures (Item 2). Treatment evaluation requires daily tracking of the ANC and temperature trends (Item 3). If this ongoing monitoring reveals persistent fever after 4 to 7 days of appropriate antibacterial coverage, occult fungal infection becomes highly probable, necessitating the addition of empiric antifungals (Item 4). Finally, the empiric regimen should only be discontinued once the patient has demonstrated sustained defervescence and immune recovery, defined by an ANC greater than 500 cells/mm³ (Item 5).

Step-by-Step Solution

1
Obtain blood cultures from the PICC line and a peripheral site.
Samples are secured prior to sterilization of the bloodstream.
To accurately identify the causative pathogen and allow for later targeted de-escalation of antibiotics.
2
Administer an empiric antipseudomonal beta-lactam antibiotic.
Broad-spectrum coverage is initiated within 60 minutes.
Febrile neutropenia is a rapidly fatal medical emergency requiring immediate empiric coverage against high-risk organisms like Pseudomonas aeruginosa.
3
Monitor the patient's daily ANC and fever curve.
The clinical trajectory and immune system recovery are continuously evaluated.
To assess whether the initial empiric therapy is effective and to inform subsequent treatment modifications.
4
Add an empiric antifungal agent if the fever and profound neutropenia persist for 4 to 7 days.
Coverage is expanded to include invasive fungal pathogens.
Persistent fever despite broad-spectrum antibacterial therapy in a neutropenic patient strongly suggests an occult fungal infection (e.g., Candida or Aspergillus).
5
Discontinue all antimicrobial therapy.
Empiric treatment is safely concluded without premature cessation.
Discontinuation is only safe once the patient is afebrile for 48 hours and the ANC has recovered to >500 cells/mm³, indicating sufficient immune reconstitution.

Key Concept

Sequential evaluation and protocol-driven therapeutic modification in the management of high-risk febrile neutropenia.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic